Focus: Novo Nordisk is a Danish pharma giant dominating the GLP-1 and insulin markets with $9.2B in annual Ozempic sales alone, making it a global leader in diabetes and obesity care.
Profile data last refreshed 6h ago · AI intelligence enriched 2w ago
2 recent layoff filings (12 mo) — 1,622 affected
Source: state DOL filings via Big Local News
No open roles listed right now. Follow Novo Nordisk to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Novo Nordisk
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Novo Nordisk's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Flagship revenue driver capturing 60% of total company sales; supply constraints from record demand underpin pricing power.
Oral alternative to Ozempic expanding addressable market in patients avoiding injections; peak growth phase.
Long-acting insulin backbone of portfolio; mature product with stable royalties protecting margin through biosimilar entry.
Rapid-acting insulin facing generic/biosimilar pressure; declining revenue typical of mature basal-bolus regimen displacement.
15 discontinued, 13 duplicate formulations not shown
+3 more products with revenue data
No open positions listed yet. Check their careers page directly.
Based on last 3 crawl cycles
Source: USCIS H-1B Employer Data Hub
+4 more products
Source: state DOL filings, aggregated via Big Local News
Ozempic shortage driven by demand surge, not manufacturing or quality issues; no recent layoffs or FDA warnings indicate stable operations.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo